OTCMKTS:IMNPQ Immune Pharmaceuticals (IMNPQ) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free IMNPQ Stock Alerts $0.0010 0.00 (0.00%) (As of 08/17/2022) Add Compare Share Share Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.0001▼$0.0070VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immune Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Immune Pharmaceuticals Stock (OTCMKTS:IMNPQ)Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.Read More IMNPQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNPQ Stock News HeadlinesApril 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Robinhood, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 10, 2024 | money.usnews.comVertex Pharmaceuticals to Buy Alpine Immune Sciences for $4.9 BillionApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 10, 2024 | marketwatch.comAlpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.April 10, 2024 | msn.comVertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune dealFebruary 5, 2024 | reuters.comJ&J's immune disorder drug succeeds in studiesDecember 20, 2023 | seekingalpha.comAC Immune: Initial AD Findings Bring About Two Upcoming CatalystsDecember 20, 2023 | forbes.comBest Vitamins And Foods To Boost Your Immune SystemApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 15, 2023 | markets.businessinsider.comAC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b TrialAugust 21, 2023 | msn.comRegeneron’s Veopoz scores FDA approval for rare immune diseaseAugust 21, 2023 | msn.comFDA Approves Regeneron's Drug For Ultra Rare Immune DisorderAugust 18, 2023 | seekingalpha.comRegeneron wins approval for rare immune disease therapy pozelimabJuly 28, 2023 | benzinga.comNatural Immune Booster Market to Reach $19.67 Billion by 2030, Says Coherent Market Insights (CMI)April 22, 2023 | marketwatch.comImmune Check Point Inhibitor Market Size, Latest Trends, Key Players, Revenue, Report, And Forecast 2031March 28, 2023 | marketwatch.comHuman Immune Health Supplements Market Size and New Revenue Techniques By 2031March 24, 2023 | marketwatch.comNatural Immune Booster Market Top Players By 2031March 6, 2023 | usnews.comJudge: Oxford Schools, Staff Immune From Shooting LawsuitsMarch 1, 2023 | benzinga.comImmune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and DirectionFebruary 28, 2023 | marketwatch.comGlobal Natural Immune Booster Market Report Historical, Current, and Projected Size, in terms of value 2030 By VMReportsJanuary 14, 2023 | foxnews.comChelsea Handler declares she's immune to cancel culture because she's not ‘racist,’ ‘sexist’ ‘idiot’January 14, 2023 | cnn.comStudy shows convalescent plasma works for immune-compromised Covid-19 patients, but it can be hard to findOctober 27, 2022 | theguardian.comImmune system-evading hybrid virus observed for first timeOctober 26, 2022 | reuters.comFor those with HIV or weak immune systems, monkeypox can be fatal -U.S. studyOctober 25, 2022 | yahoo.comTargeting One Type of Immune Cell With Another Slows Cancer Growth in Preclinical StudiesSeptember 12, 2022 | markets.businessinsider.comPositive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJMSeptember 7, 2022 | bizjournals.comCour Pharmaceuticals secures funding to transform the way allergies and autoimmune disorders are treatedSee More Headlines Receive IMNPQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMNPQ CUSIPN/A CIK1208261 Webwww.immunepharma.com Phone(201) 464-2677Fax917-398-1915Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John P. Clark (Age 51)Controller & Principal Accounting Officer Comp: $175kMr. Gary H. Rabin (Age 57)Interim CEO & Director Mr. Christine J. PetragliaDirector of Investor RelationsDr. Miri Ben-AmiPres of Immune Oncology Pharmaceuticals IncDr. Boris ShorExec. Director of R&D & Scientific PartnershipsMr. Ranch C. KimballStrategic AdvisorMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors IMNPQ Stock Analysis - Frequently Asked Questions How have IMNPQ shares performed in 2024? Immune Pharmaceuticals' stock was trading at $0.0010 at the beginning of 2024. Since then, IMNPQ shares have increased by 0.0% and is now trading at $0.0010. View the best growth stocks for 2024 here. What ETF holds Immune Pharmaceuticals' stock? Horizon Kinetics Medical ETF holds 1 shares of IMNPQ stock, representing 0.00% of its portfolio. How do I buy shares of Immune Pharmaceuticals? Shares of IMNPQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMNPQ) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
